Catherine Lavau

Catherine Lavau

Auto-generated profile, based on publicly available information

Catherine Lavau

Univ Rennes, Inserm, EHESP, Irset - UMR_S 1085, F-35000 Rennes, France

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 1991 in Cell
Verified
Journal Article
Closed access
HTHugues de Thé
Hugues de Thé
CLCatherine Lavau
Catherine Lavau
AMAgnès Marchio
Agnès Marchio
CCChristine Chomienne
Christine Chomienne
LDLaurent Degos
Laurent Degos
ADAnne Dejean
Anne Dejean

1 January 1994 in Cell
Verified
Journal Article
Closed access
KWKarsten Weis
Karsten Weis
SRSophie Rambaud
Sophie Rambaud
CLCatherine Lavau
Catherine Lavau
JJJoop Jansen
Joop Jansen
TCTeresa Carvalho
Teresa Carvalho
ADAnne Dejean
Anne Dejean

15 July 1997 in The EMBO Journal
Verified
Journal Article
Closed access
PDF file
CLCatherine Lavau
Catherine Lavau
SSStephen J. Szilvassy
Stephen J. Szilvassy
RSRobert Slany
Robert Slany
MCMichael L. Cleary
Michael L. Cleary

22 September 2014 in Nature Communications
Verified
Journal Article
Open access
KMKevin Moreau
Kevin Moreau
AFAngeleen Fleming
Angeleen Fleming
SISara Imarisio
Sara Imarisio
ARAna Lopez Ramirez
Ana Lopez Ramirez
JMJacob L. Mercer
Jacob L. Mercer
DRDavid C. Rubinsztein
David C. Rubinsztein
Genome-wide association studies have identified several loci associated with Alzheimer’s disease (AD), including proteins involved in endocytic trafficking such as PICALM/CALM (phosphatidylinositol binding clathrin assembly protein). It is unclear how these loci may contribute to AD pathology. Here we show that CALM modulates autophagy and alters clearance of tau, a protein which is a known autophagy substrate and which is causatively linked to AD, both in vitro and in vivo. Furthermore, altered CALM expression exacerbates tau-mediated toxicity in zebrafish transgenic models. CALM influences autophagy by regulating the endocytosis of SNAREs, such as VAMP2, VAMP3 and VAMP8, which have diverse effects on different stages of the autophagy pathway, from autophagosome formation to autophagosome degradation. This study suggests that the AD genetic risk factor CALM modulates autophagy, and this may affect disease in a number of ways including modulation of tau turnover.

1 January 1998 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
RSRobert K. Slany
Robert K. Slany
CLCatherine Lavau
Catherine Lavau
MCMichael L. Cleary
Michael L. Cleary
The HRX gene (also called MLL,ALL-1, and Htrx) at chromosome band 11q23 is associated with specific subsets of acute leukemias through translocations that result in its fusion with a variety of heterologous partners. Two of these partners, ENL and AF9, code for proteins that are highly similar to each other and as fusions with HRX induce myeloid leukemias in mice as demonstrated by retroviral gene transfer and knock-in experiments, respectively. In the present study, a structure-function analysis was performed to determine the molecular requirements for in vitro immortalization of murine myeloid cells by HRX-ENL. Deletions of either the AT hook motifs or the methyltransferase homology domain of HRX substantially impaired the transforming effects of HRX-ENL. The methyltransferase homology domain was shown to bind non-sequence specifically to DNA in vitro, providing evidence that the full transforming activity of HRX-ENL requires multiple DNA binding structures in HRX. The carboxy-terminal 84 amino acids of ENL, which encode two predicted helical structures highly conserved in AF9, were necessary and sufficient for transformation when they were fused to HRX. Similarly, mutations that deleted one or both of these conserved helices completely abrogated the transcriptional activation properties of ENL. This finding correlates, for the first time, a biological function of an HRX fusion partner with the transforming activity of the chimeric proteins. Our studies support a model in which HRX-ENL induces myeloid transformation by deregulating subordinate genes through a gain of function contributed by the transcriptional effector properties of ENL.

1 September 2000 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
CLCatherine Lavau
Catherine Lavau
CDChangchun Du
Changchun Du
MTMichael Thirman
Michael Thirman
NZNancy Zeleznik‐Le
Nancy Zeleznik‐Le
As a result of the recurring translocation t(11;16) (q23;p13.3), MLL (mixed‐lineage leukemia) is fused in frame to CBP (CREB binding protein). This translocation has been documented almost exclusively in cases of acute leukemia or myelodysplasia secondary to therapy with drugs that target DNA topo isomerase II. The minimal chimeric protein that is produced fuses MLL to the bromodomain, histone acetyltransferase (HAT) domain, EIA‐binding domain and steroid‐receptor coactivator binding domains of CBP. We show that transplantation of bone marrow retrovirally transduced with MLL–CBP induces myeloid leukemias in mice that are preceded by a long preleukemic phase similar to the myelodysplastic syndrome (MDS) seen in many t(11;16) patients but unusual for other MLL translocations. Structure–function analysis demonstrated that fusion of both the bromodomain and HAT domain of CBP to the amino portion of MLL is required for full in vitro transformation and is sufficient to induce the leukemic phenotype in vivo . This suggests that the leukemic effect of MLL–CBP results from the fusion of the chromatin association and modifying activities of CBP with the DNA binding activities of MLL.